FY 23-24 was a pivotal year that tested our adaptability and resilience in various ways. Our strategic emphasis on formulations helped maintain a steady turnover and increased our value-added percentage, despite cyber incidents, declining Paracetamol API volumes, and market price erosion.
Download SectionOver the past four decades, Granules India has emerged as a high-growth, vertically integrated pharmaceutical company with consistent performance and a growing global footprint.
We have carved a distinct position in the global pharmaceutical sector by delivering superior quality API, PFI and FD through manufacturing excellence, process innovation and proven regulatory expertise.
At Granules, we take pride in our diverse portfolio across Active Pharmaceutical Ingredients (API), Pharmaceutical Formulations Intermediates (PFI), and Finished Dosage (FD). These segments showcase our commitment to pioneering solutions in pharmaceutical manufacturing, enhancing efficiency, and meeting global healthcare needs with cutting-edge innovation.
Download SectionShare of revenues from our FD business on FY 23-24
Share of revenues from our API business on FY 23-24
Share of revenues from our PFI business on FY 23-24
Our strategic framework revolves around strengthening our core, driving R&D and innovation, and advancing sustainability.
Our strategic focus lies in improving API and formulations manufacturing productivity, optimizing sourcing and logistics, and implementing a commercial excellence program to strengthen our market presence and expand customer share.
Aligned with our strategic vision of transforming into an R&D-driven organization, we are actively augmenting our product development capabilities. Through these advancements, we aim to broaden our overall capabilities, elevate the quality of our portfolio, and significantly increase the number of regulatory filings.
Sustainability is a guiding principle in our strategic vision and decision-making process, integrating environmental and social considerations with our business objectives.
The pharmaceutical industry has a dual responsibility: to heal lives and to heal the planet. Through innovative strategies and sustainable practices, we can drive our industry towards decarbonization and contribute significantly to a carbon-neutral future.
DR. KRISHNA PRASAD CHIGURUPATIChairman and Managing Director
Absolute reduction in GHG emissions (Scope 1 and 2)
Of electricity consumption from renewable sources (PPA, rooftop solar, and I-RECs)
Of our waste water is recycled
Hazardous waste sent for reused (co-processing)
Of vendors engaged to determine product carbon footprint and climate commitment
Employees
Female employees
Increase in female employees
Return-to-work rate
Students trained through Pharma Pathshala
Confirmed cases of discrimination
Women on the Board
We developed a comprehensive strategy in FY 23-24 to realize our sustainability vision, setting in motion specific targets and initiatives across three identified pillars:
The Board is responsible for overseeing the implementation, reviewing progress, and recommending course corrections where needed.
We strive to balance our operational needs with our commitment to minimizing environmental footprint. To deliver a measurable positive impact across emission reduction, optimal resource use, water and waste management, we have defined time-bound targets and continuously monitor our progress against those goals.
We have committed to significantly reducing greenhouse gas emissions as part of our broader climate action strategy. By increasing the renewable energy mix in our electricity consumption and developing an Internal Carbon Pricing (ICP) system by FY 24-25, we aim to achieve substantial progress towards our climate goals.
Effective water management is a critical aspect of our environmental strategy. We are committed to reducing water intensity and improving water stewardship across all our operations.
Our waste management strategy focuses on minimizing waste generation, maximizing recycling and reuse, and reducing waste sent to landfills.
Understanding and mitigating climate risks is essential for our operations' resilience. We conduct climate risk analyses for all facilities and strategic suppliers to ensure that we are prepared for and adapt to changing climate conditions.
At Granules, we prioritize creating a conducive environment where people thrive through continuous learning, personal growth, and a strong focus on safety. Our dedication to diversity, inclusion, and employee well-being ensures everyone feels valued and empowered.
We are committed to shaping a better society through impactful healthcare, education, and community development initiatives. From empowering rural youth, supporting critical healthcare services, promoting education, and fostering sports excellence, our efforts aim to uplift communities and contribute to a brighter future.
Our Board of Directors is pivotal in overseeing and guiding our governance practices. Comprising experienced professionals from diverse backgrounds, the Board sets the strategic direction and monitors compliance with regulatory requirements and ethical standards. Their leadership ensures that Granules operates with the highest integrity and ethical conduct.
Board Composition
At Granules, we recognize the importance of a robust risk management system that aligns business decisions with identified and emerging risks. Our risk management policy and framework provides a comprehensive view of our risk exposures and facilitates proactive mitigation.
Download SectionWe take pride in the prestigious awards and recognitions that Granules India Limited has received over the past year. These accolades honor our relentless pursuit of quality and innovation and highlight our commitment to sustainability, leadership excellence, and future readiness.
Download Section